Health
FDA Grants Breakthrough Device Designation to Tempus’ Atrial Fibrillation ECG Analysis Platform, Developed in Collaboration With Geisinger – Business Wire
Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food & Drug Administration (FDA) has granted the
CHICAGO–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device Designation for its ECG Analysis Platform. The platform, developed in collaboration with Geisinger, aids clinicians in identifying patients at increased risk of developing atrial fibrillation (AFib) or atrial flutter. Breakthrough Designation entitles the platform to an expedited regulatory process.
…
-
General20 hours agoOf saints and sinners | The Spectator Australia
-
General20 hours agoSmall plane crashes into San Diego neighbourhood, setting homes and vehicles on fire
-
Noosa News10 hours agoTully Sugar Mill celebrates 100 years of cane harvesting amid floods and cyclones
-
General20 hours agoWhy the nation needs the Nationals to ditch Net Zero